iOrgan Bio

Supplying Cells to Improve the Human Condition

iOrgan Bio is a company in ai machine learning based in United States, founded in 2025.

Profile

iOrgan Bio is redefining how human cells are made by turning biology into an industrial, data-defined process. Built on technology from Weill Cornell Medicine and the Terasaki Institute, the company’s CellForge platform uses AI-driven, multi-omics feedback control to guide cells toward exact target states without genetic modification. This enables reproducible manufacturing of any human cell type or organoid with unmatched bioequivalence and cost efficiency. By standardizing living cell production, iOrgan Bio provides the foundation for scalable disease modeling, regenerative medicine, and cell therapy manufacturing—at up to 100× lower cost than today’s methods. Led by experts from MD Anderson, Weill Cornell, and top biotech companies, iOrgan Bio is transforming human cells from bespoke materials into reliable, mass-manufactured products.

Within the ai machine learning space, the company focuses on its core offering rather than a broad product line.

Its base of operations is United States.

Directory data places it at the SOSV portfolio company stage.

Its team size is recorded as 2-10 employees.

Website: iorgan.bio